COLUMBIA, S.C., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Absolute Total Care, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer South Carolinians a variety of affordable health insurance plans in plan year 2025. Open enrollment for the Health Insurance Marketplace for South Carolina runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"Ambetter from Absolute Total Care offers a variety of coverage options and health solutions designed to meet each individuals' unique needs," said President and CEO, Absolute Total Care, John McClellan. "Our commitment is not just to provide high quality insurance, but to build a healthier South Carolina for all, where every member feels valued, supported and equipped to thrive."
Ambetter from Absolute Total Care offers quality care, convenient services and valuable rewards that help make health insurance fit within people's lives:
South Carolina residents interested in learning more about Ambetter from Absolute Total Care or enrolling in a health plan during the open enrollment period may visit ambetter.absolutetotalcare.com.
About Ambetter from Absolute Total Care & Ambetter Health
Ambetter from Absolute Total Care serves under-insured and uninsured populations through the federal Health Insurance Marketplace. Ambetter from Absolute Total Care is underwritten by Absolute Total Care, Inc., which is a Qualified Health Plan issuer in South Carolina. Ambetter Health, offering the Ambetter Health Solutions product, is underwritten by Celtic Insurance Company. For more information visit ambetterhealth.com/en/sc. This is a solicitation for insurance. For information on your right to receive an Ambetter from Absolute Total Care plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$29.04 |
Daily Change: | 0.66 2.33 |
Daily Volume: | 7,803,803 |
Market Cap: | US$14.260B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load